Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for UroGen Pharma (URGN) over the last 10 years, with Q3 2025 value amounting to $127.0 million.

  • UroGen Pharma's Cash & Current Investments fell 4910.03% to $127.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $127.0 million, marking a year-over-year decrease of 4910.03%. This contributed to the annual value of $236.7 million for FY2024, which is 7280.31% up from last year.
  • Latest data reveals that UroGen Pharma reported Cash & Current Investments of $127.0 million as of Q3 2025, which was down 4910.03% from $157.0 million recorded in Q2 2025.
  • UroGen Pharma's 5-year Cash & Current Investments high stood at $249.6 million for Q3 2024, and its period low was $47.3 million during Q2 2023.
  • Over the past 5 years, UroGen Pharma's median Cash & Current Investments value was $127.0 million (recorded in 2025), while the average stood at $135.3 million.
  • Per our database at Business Quant, UroGen Pharma's Cash & Current Investments crashed by 5232.18% in 2023 and then soared by 40966.79% in 2024.
  • UroGen Pharma's Cash & Current Investments (Quarter) stood at $89.1 million in 2021, then increased by 12.14% to $100.0 million in 2022, then soared by 37.02% to $137.0 million in 2023, then skyrocketed by 72.8% to $236.7 million in 2024, then plummeted by 46.33% to $127.0 million in 2025.
  • Its Cash & Current Investments stands at $127.0 million for Q3 2025, versus $157.0 million for Q2 2025 and $195.9 million for Q1 2025.